Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Completed 5Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Parkinson Disease 4, Autosomal Dominant Lewy Body 21Breast Neoplasms 17Neoplasms 16Multiple Myeloma 16Leukemia, Myeloid, Acute 15Recurrence 10Colorectal Neoplasms 10Myelodysplastic Syndromes 9Lymphoma, Non-Hodgkin 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Lymphoma, Follicular 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Stomach Neoplasms 6Ovarian Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Purpura, Thrombocytopenic, Idiopathic 5Neoplasm Metastasis 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Graft vs Host Disease 5Esophageal Neoplasms 5Bronchiolitis Obliterans Syndrome 5Adenocarcinoma 5

Interventions

tisotumab vedotin 2pembrolizumab 2Cisplatin 2sacituzumab govitecan 1Vinorelbine 1Topotecan 1Saline Solution 1Pemetrexed 1Paclitaxel 1Irinotecan 1Gemcitabine 1Carboplatin 1Brachytherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Has announcements × Uterine Cervical Neoplasms × Clear all
NCT04697628 2026-02-24

innovaTV 301

Seagen Inc.

Phase 3 Completed
502 enrolled 18 charts 1 FDA
Gynecologic

Uterine Cervical Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

Merck Sharp & Dohme LLC

Phase 3 Completed
1,060 enrolled 30 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Merck Sharp & Dohme LLC

Phase 3 Completed
617 enrolled 29 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03438396 2023-07-25

A Trial of Tisotumab Vedotin in Cervical Cancer

Seagen Inc.

Phase 2 Completed
102 enrolled 20 charts 1 FDA
Gynecologic

Uterine Cervical Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡